Literature DB >> 16912528

[Clinicopathological characteristics of gastric cancer in elderly patients].

Nantetsu Boku1, Rumiko Okamoto, Kouji Kandabashi, Eisaku Sasaki, Yasushi Omuro, Yoshiharu Maeda, Tsuneo Sasaki.   

Abstract

Careful consideration must be given to the efficacy of treatment for elderly patients with advanced gastric cancer. Thirty-two elderly patients, 75 years of age or older with gastric cancer, were treated in Tokyo Metropolitan Komagome Hospital,Department of Chemotherapy, between January, 1993 to December, 2002. We analyzed the data of these patients retrospectively. The male/female ratio was 13:3, and 90.6% of the patients developed complications. Some 29 patients were treated with 5-FU regimen. The response rate was 17.2%, median survival time was 201 days, and 5 PR pts had 421 days' survival time. Patients with good PS had long survival times. A comparative study was conducted between 15 cases treated with cisplatin (CDDP) regimen and 14 cases without CDDP. Among them, 13 pts were given a low dose and 16 pts a full dose of chemotherapy (5-FU+/-CDDP). No differences were found between the two groups in overall survival time. No patients showed a severe adverse effect and some exhibited improvement by the chemotherapy. Therefore, the choice of chemotherapy for an elderly gastric cancer patient mostly depends on the patient' s general condition. Elderly patients can develop many complications, so the organ function test should be carefully evaluated. Development of an oral anticancer drug for gastric cancer is in progress and promises to show good results in the near future. Chemotherapy appears able to preserve good "Quality of Life" and will play an important role in the treatment of gastric cancer in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912528

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Authors:  Akitaka Makiyama; Kenji Kunieda; Masaaki Noguchi; Takeshi Kajiwara; Takao Tamura; Koji Takeda; Junko Sugiyama; Keiko Minashi; Toshikazu Moriwaki; Naotoshi Sugimoto; Michitaka Nagase; Yuji Negoro; Takashi Tsuda; Hideki Shimodaira; Naohiro Okano; Akihito Tsuji; Daisuke Sakai; Kazuhiro Yanagihara; Shinya Ueda; Shingo Tamura; Satoshi Otsu; Takuya Honda; Yuzo Matsushita; Tatsuya Okuno; Tomomi Kashiwada; Akira Nozaki; Masahide Ebi; Hiroyuki Okuda; Mototsugu Shimokawa; Shuichi Hironaka; Ichinosuke Hyodo; Eishi Baba; Narikazu Boku; Kei Muro; Taito Esaki
Journal:  Gastric Cancer       Date:  2018-01-20       Impact factor: 7.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.